Oncotype DX breast tests for Leeds hospitals come from Exact Sciences
- Leeds Teaching Hospitals NHS Trust
- Yorkshire and the Humber
- Call-off from a framework agreement
- 1 July 2026 to 30 June 2028
Leeds Teaching Hospitals NHS Trust is buying the Oncotype DX Breast Recurrence Score test from Exact Sciences. The multigene test predicts how likely a breast cancer patient is to benefit from chemotherapy.
Exact Sciences is the only source of the test on the global market. The trust ordered directly through the NHS Supply Chain framework for Laboratory Diagnostics, Point of Care Testing and Pathology Managed Services. Exact Sciences gave a discounted price per test, with the order based on 250 tests over two years.
The £337,500 contract runs from July 2026 to June 2028, with an option to extend by 12 months if the supplier agrees.
Contract ends June 2028
- What
- Pathology and specialist laboratory testing services
- Supplier
- Exact Sciences
- Value
- £337,500
- How it was bought
- Call-off from a framework agreement
- Dates and next
- Jul 2026 to Jun 2028